Business Wire

LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

23.2.2021 01:33:00 EET | Business Wire | Press release

Share

LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.

LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.

LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.

“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”

Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”

According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”

About LG Chem Life Sciences

LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.

LG Chem Life Sciences Innovation Center: innovation.lgchem.com

About TransThera Biosciences

TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Adtran launches Ensemble Cloudlet multi‑node to simplify high‑availability edge AI deployments8.4.2026 15:30:00 EEST | Press release

Adtran today launched its Ensemble Cloudlet multi‑node solution, a high‑availability edge platform that supports AI inference and agentic AI deployments where low latency, resilience and secure local processing are critical. Removing the complexity and cost barriers that slow modern service and enterprise deployments, the solution creates a single, logical cloud with distributed storage and automated failover, starting with just two nodes. Built on Cloudlet OS and managed through Ensemble EdgeView orchestration, it enables zero-touch deployment and unified lifecycle management, providing a simple, scalable foundation for running networking, IT and emerging AI workloads at the edge. “Deploying high‑availability edge infrastructure for AI has often demanded a lot of cloud wizardry – stitching together storage, networking and failover manually. With Ensemble Cloudlet multi‑node, we’ve made the hard parts easy,” said Christoph Glingener, CTO of Adtran. “The nodes build their own shared sto

ZincFive Announces Nickel-Zinc Retrofit Kit to Modernize Existing UPS Energy Storage Infrastructure8.4.2026 15:05:00 EEST | Press release

ZincFive®, the global leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced the NiZn Retrofit Kit, an uninterruptible power supply (UPS) energy storage solution designed to bring the benefits of modern battery chemistry to existing UPS battery systems in mission-critical environments. The NiZn Retrofit Kit will enable data center operators and service providers to replace legacy valve-regulated lead-acid (VRLA) batteries with ZincFive’s long-life, high-performance nickel-zinc technology without requiring cabinet enclosure replacement, system redesign, or operational disruption. As data center power demands continue to increase, operators face growing pressure to improve reliability, reduce lifecycle costs, and meet sustainability targets. At the same time, much of the global UPS energy storage system installed base remains constrained by legacy VRLA batteries, where full storage system replacement introduces significant cost, complexity,

Sagard and Unigestion Announce Closing of Partnership Transaction8.4.2026 15:00:00 EEST | Press release

Sagard, a global multi-strategy alternative asset management firm with over $45 billion USD1 in assets under management and Unigestion Private Equity Holding SA (UNG PE), a leading middle market private equity provider, today announced the successful closing of their combination transaction, originally announced in September. Completion of this transaction marks the formal launch of the partnership and the integration of UNG PE into Sagard’s global middle-market private equity platform, Sagard Private Equity Solutions (SPES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408374851/en/ “We are thrilled to formally begin our partnership with the Unigestion team,” said Paul Desmarais III, Chairman & CEO of Sagard. “This milestone solidifies our joint commitment to building a global private equity platform positioned for long-term growth alongside our clients and teams.” “The closing of this transaction represents an excitin

New Research Finds AI Is Now Foundational to Modern Marketing8.4.2026 15:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced its participation in a new marketing research study conducted by Callan Consulting, a Silicon Valley executive marketing consulting firm, joining 18 B2B and B2C technology companies to examine how AI is reshaping modern marketing organizations, marking a clear shift from early experimentation to embedded, enterprise‑wide adoption. According to the State of AI in Technology Marketing 2026 report, based on in‑depth interviews with CMOs and senior marketing leaders at the participating companies, the study finds that AI is becoming rapidly integrated across core marketing teams and workflows—from content development and research to campaign optimization and analytics. As adoption deepens, data quality, accessibility, and governance are emerging as critical priorities. "AI doesn't change what great marketing is supposed to do. It just removes the excuses for not doing it," said Gabie Boko, Chief Marketing

Telia to Deploy Seamless OS Following Acquisition of Telness Operator8.4.2026 14:16:00 EEST | Press release

Today, Nordic Communications Group AB, parent company of Telness Tech, announced it will divest its mobile virtual network operator (MVNO) Telness to Telia in Sweden. As part of the transaction, Telness will sign a long-term agreement with Telness Tech for continued use of the Seamless OS technology platform, ensuring a smooth digital customer experience. At closing, Telia will become the first mobile network operator (MNO) to deploy Seamless OS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408876675/en/ Telness Tech executive leadership team on the announcement that Telia will be the first Mobile Network Operator (MNO) deploying Seamless OS. From the left, Sergio Budkin; CRO, Martina Klingvall; Founder and CEO, Sebastian Stecki; CMO, Pablo Noguerol; COO, Christina Berggren; VP Customer, Delivery & Product, Jonas Cedenwing; Founder and CTO. "For Seamless OS to be brought into an MNO environment such as Telia's is a defi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye